Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
Vittorio eDonato, Stefano eArcangeli, Alessia eMonaco and 6 more
Frontiers in Oncology · 2013
doi:10.3389/fonc.2013.00286 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Purpose To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-Modulated Technique in combination with sequential or concurrent chemotherapy.Methods and Materials Sixty-one consecutive patients considered non-progressive after 2 cycles of induction chemotherapy were treated with a moderately escalated hypofractionated radiation course of 30 daily fractions of 2.25-2.28 Gy each administered in 6 weeks up to a total dose of 67.5 Gy–68.4 Gy (range, 64.5 Gy–71.3 Gy). Thirty-two received sequential RT after 2 more cycles (total= 4 cycles) of chemotherapy, while twenty-nine were treated with concurrent chemo-radiation. The target was considered the gross tumour volume and the clinically proven nodal regions, without elective nodal irradiation. Results With a median follow up of 27 months (range 6 to 40), one-year and 2-year OS rate for all patients was 77% and 53% respectively, with a median survival duration of 18.6 months in the sequential group and 24.1 months in the concomitant group. No Grade ≥ 4 acute and late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in 10% of patients. Two patients, both receiving the concurrent schedule, developed a Grade 3 acute esophagitis. The overall incidence of late Grade 3 lung toxicity was 5%. No patients experienced a Grade 3 late esophageal toxicity.Conclusions A moderately hypofractionated radiation course delivered with a Helical Intensity-Modulated Technique is a feasible treatment option for patients with unresectable locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofractionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing the effect of tumor repopulation that may occur with prolonged treatment time.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.